Einmal drehen bitte.

skin cancer

OncoBeta GmbH and Australian Nuclear Science and Technology Organisation sign Letter of Intent to establish manufacturing site in Australia

von

Innovative medical device Rhenium-SCT® therapy for non-melanoma skin cancer of the gate-startup to be produced in Australia OncoBeta® GmbH, a commercial stage medical device company specialized in innovative epidermal radioisotope therapies for non-melanoma skin cancers and the Australian Nuclear Science and Technology Organisation (ANSTO), are pleased to announce that they have signed a Letter of … Weiterlesen

gate-Startup OncoBeta and RadioMedix announce exclusive distribution agreement for W/Re-188 generators in U.S. and Canada

von

RadioMedix and OncoBeta today announced the execution of an exclusive distribution agreement for the next generation of W/Re-188 generators in the U.S. and Canada. The OncoBeta® Tungsten (Wolfram)-188/Rhenium-188 (W/Re-188) Generators can be used for radiolabeling reactions or directly as a high dose liquid radioactive source. Rhenium-188 (Re-188) is a high energy-emitting radioisotope obtained from the … Weiterlesen

gate-Startup OncoBeta® receives Corporate Excellence Award 2019

von
Application OncoBeta

OncoBeta® has recently been presented with the CV Magazine’s Corporate Excellence Award for the Most Compassionate Skin Cancer Therapy Provider in 2019. The Medical Device Company specialized in innovative epidermal radioisotope therapies for Non-Melanocytic Skin Cancers (NMSCs) residents at the business incubator gate in Garching, Munich. CV Magazine’s annual Corporate Excellence Awards are handpicked by … Weiterlesen